House Dust Mite Allergy - Pipeline Review, H1 2019

Global Markets Direct’s, ‘House Dust Mite Allergy - Pipeline Review, H1 2019’, provides an overview of the House Dust Mite Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for House Dust Mite Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy

- The report reviews pipeline therapeutics for House Dust Mite Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved House Dust Mite Allergy therapeutics and enlists all their major and minor projects

- The report assesses House Dust Mite Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for House Dust Mite Allergy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for House Dust Mite Allergy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding House Dust Mite Allergy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ALK-Abello AS

Allergy Therapeutics Plc

Anergis SA

ASIT Biotech SA

Biomay AG

Genetic Immunity Inc

Stallergenes Greer plc

Zhejiang I-Biological Technology Co Ltd

ALK-Abello AS

Allergy Therapeutics Plc

Anergis SA

ASIT Biotech SA

Biomay AG

Genetic Immunity Inc

Stallergenes Greer plc

Zhejiang I-Biological Technology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

House Dust Mite Allergy - Overview

House Dust Mite Allergy ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

House Dust Mite Allergy - Overview

House Dust Mite Allergy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

House Dust Mite Allergy - Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

House Dust Mite Allergy - Companies Involved in Therapeutics Development

ALK-Abello AS

Allergy Therapeutics Plc

Anergis SA

ASIT Biotech SA

Biomay AG

Genetic Immunity Inc

Stallergenes Greer plc

Zhejiang I-Biological Technology Co Ltd

House Dust Mite Allergy - Drug Profiles

Allergan for Dust Mite Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Asthma and House Dust Mite Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BM-35 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DermAll-HDM - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hdm-ASIT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

house dust mite (Dermatophagoides farinae) allergen extract - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for House Dust Mite Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

House Dust Mite Allergy - Dormant Projects

House Dust Mite Allergy - Discontinued Products

House Dust Mite Allergy - Product Development Milestones

Featured News & Press Releases

Nov 20, 2018: Stallergenes Greer announces that the phase III trial for its sublingual allergy immunotherapy tablet STAGR320 to treat house dust mite-induced allergic rhinitis achieved its primary endpoint

May 29, 2018: Allergy Therapeutics - Positive new data with house-dust mite immunotherapy

Feb 21, 2018: New medicine for house dust mite allergic rhinitis and allergic asthma now available in France

Feb 16, 2018: Shionogi Got Approval of Partial Change Application in Dosage and Administration in Japan of Actair for Allergen Immunotherapy of Pediatric Allergic Rhinitis Caused by House Dust Mites

Feb 16, 2018: Torii Receives Approval for Additional Dosage and Administration for Pediatric Indication for MITICURE House Dust Mite Sublingual Tablets

Jan 11, 2018: New Treatment for House Dust Mite (HDM) - Induced Allergic Rhinitis Now Available in US

Nov 30, 2017: ALK secures pricing and reimbursement for ACARIZAX in France

Nov 23, 2017: European Patent Office Grants to ASIT biotech a Second Patent Related to the Active Ingredients Used in the ASIT+ Allergy Immunotherapy Product Candidates

Oct 24, 2017: ASIT biotech Publishes the Results of The hdm-ASIT+ Phase I/II Follow-up Study in House Dust Mite Rhinitis

Sep 26, 2017: Stallergenes Greer Advances Its House Dust Mite Allergy Pipeline With Acceptance Of Regulatory Submission And New Market Approval

Aug 21, 2017: ALK to accelerate launches of ODACTRA in the USA / ACARIZAX in Canada

Aug 16, 2017: ASIT biotech Announces the Approval by the Regulatory Authorities of a Follow-up Study of the Phase I/IIa Clinical Trial with its hdm-ASIT Product Candidate for House Dust Mite Rhinitis

Jul 27, 2017: Stallergenes Greer Announces Completion of Enrollment in Largest Phase III Study to Treat House Dust Mites Allergy

May 04, 2017: ALK's HDM SLIT-tablet, ACARIZAX, approved in Canada

Apr 16, 2017: ACARIZAX approved in Europe for use in adolescent patients with house dust mite-induced allergic rhinitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for House Dust Mite Allergy, H1 2019

Number of Products under Development by Companies, H1 2019

Products ...

List of Tables

Number of Products under Development for House Dust Mite Allergy, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

House Dust Mite Allergy - Pipeline by ALK-Abello AS, H1 2019

House Dust Mite Allergy - Pipeline by Allergy Therapeutics Plc, H1 2019

House Dust Mite Allergy - Pipeline by Anergis SA, H1 2019

House Dust Mite Allergy - Pipeline by ASIT Biotech SA, H1 2019

House Dust Mite Allergy - Pipeline by Biomay AG, H1 2019

House Dust Mite Allergy - Pipeline by Genetic Immunity Inc, H1 2019

House Dust Mite Allergy - Pipeline by Stallergenes Greer plc, H1 2019

House Dust Mite Allergy - Pipeline by Zhejiang I-Biological Technology Co Ltd, H1 2019

House Dust Mite Allergy - Dormant Projects, H1 2019

House Dust Mite Allergy - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for House Dust Mite Allergy, H1 2019

Number of Products under Development by Companies, H1 2019

Number ...

List of Figures

Number of Products under Development for House Dust Mite Allergy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports